Spruce Biosciences (SPRB) Other Non Operating Income (2019 - 2024)
Spruce Biosciences (SPRB) posted quarterly Other Non Operating Income of $808000.0 for Q3 2024, down 43.22% year-over-year from $1.4 million in Q4 2023, and down 13.86% quarter-over-quarter from $938000.0 in Q2 2024.
Spruce Biosciences (SPRB) Other Non Operating Income (2019 - 2024) Analysis & Trends
Spruce Biosciences (SPRB) has reported Other Non Operating Income for 6 consecutive years, with $808000.0 the latest figure, recorded in Q3 2024.
- In Q3 2024, Other Non Operating Income fell 43.22% year-over-year to $808000.0; the TTM figure through Sep 2024 stood at $4.3 million (up 27.93% YoY), while the FY2021 annual figure was $119000.0, down 40.5% from the prior year.
- Other Non Operating Income slipped to $808000.0 in Q3 2024 per SPRB's latest filing, from $938000.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $1.4 million in Q3 2023 and bottomed at $19000.0 in Q1 2021.
- Historically, Other Non Operating Income has averaged $410562.5 across 5 years, with a median of $66500.0 in 2020.
- Annual changes were most pronounced in 2021 — Other Non Operating Income plunged 51.28% — and 2023, when it soared 1125.96%.
- Spruce Biosciences' Other Non Operating Income stood at $75000.0 in 2020, then sank by 48.0% to $39000.0 in 2021, then surged by 166.67% to $104000.0 in 2022, then jumped by 1268.27% to $1.4 million in 2023, then tumbled by 43.22% to $808000.0 in 2024.
- Business Quant data shows SPRB's Other Non Operating Income at $808000.0 in Q3 2024, $938000.0 in Q2 2024, and $1.1 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Spruce Biosciences | 119.20 Mn | 119.20 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 808,000.00 |
| Jun 30, 2024 | 938,000.00 |
| Mar 31, 2024 | 1.11 Mn |
| Sep 30, 2023 | 1.42 Mn |
| Jun 30, 2023 | 1.28 Mn |
| Mar 31, 2023 | 539,000.00 |
| Jun 30, 2022 | 104,000.00 |
| Mar 31, 2022 | 58,000.00 |
| Dec 31, 2021 | 39,000.00 |
| Sep 30, 2021 | 41,000.00 |
| Jun 30, 2021 | 20,000.00 |
| Mar 31, 2021 | 19,000.00 |
| Dec 31, 2020 | 75,000.00 |
| Sep 30, 2020 | 51,000.00 |
| Jun 30, 2020 | 35,000.00 |
| Mar 31, 2020 | 39,000.00 |
| Dec 31, 2019 | 12,000.00 |
| Sep 30, 2019 | 18,000.00 |